SaweJ.High-dose morphine and methadone in cancer patients: clinical pharmacokinetic considerations of oral treatment. Clinical Pharmacokinetics1986; 11: 87–106.
4.
HoskinPJ, HanksGW, HeronCW. M6G and its analgesic action in chronic use. Clin J Pain1989; 5: 199–200.
5.
HanksGW, HoskinPJ, AhemeGW. Explanation for potency of repeated oral doses of morphine. Lancet1987; 723–724.
6.
WolffJ, BiglerD, ChristensenCB. Influence of renal function on the elimination of morphine and morphine glucuronides. Eur J Clin Pharmacol1988; 34: 353–357.
7.
ChanGLC, MatzkeGR. Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Drug Intell Clin Pharm1987; 21: 773–782.
8.
BrueraE, BrenneisC, MacDonaldRN. Continuous SC infusion of narcotics for the treatment of cancer pain: an update. Cancer Treat Rep1987; 71: 953–958.
9.
Arzneimittel-Kompendium der Schweiz, Ausgabe1991.
10.
OsborneRJ, JoelSP, SlevinML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J1986; 292: 1548–1549.
11.
HarbertJC. Radionuclide therapy of bone pain. In: Nuclear Medicine Therapy. New York: Thieme Medical Publishers1987: pp. 207–219.
12.
MoralesA, ConnallyJG, BurrRC, . The use of radioactive phosphorus to treat bone pain in metastatic carcinoma of the prostate. Can Med Assoc J1970; 103: 372.
13.
StiefelF.“Age and the Syndrome of Delirium” — ein Workshop des National Institute of Mental Health, Washington D.C., Juni 1989. Schweiz Rundschau Med (PRAXIS)1989; 78: 1329.
